GlassScriptPhysician profile
Dafina Wise Allen
NPI 1811288400
$1,311.65
in general payments reported to CMS, 2019-2025
18 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.63 · 2020: $15.11 · 2021: $96.44 · 2022: $94.65 · 2023: $156 · 2024: $452 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.55 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.63 | 2021-2025 | Wegovy |
| Abbvie INC. | $155.02 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $136.23 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $127.79 | 2024-2025 | Rexulti, Abilify Maintena |
| Janssen Biotech, INC. | $94.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $92.76 | 2024-2025 | Austedo Xr, Austedo Xr |
| Indivior INC. | $54.88 | 2024-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $52.26 | 2025 | |
| Lundbeck LLC | $46.64 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $41.72 | 2024-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.79 | 2024-2025 | Caplyta |
| Inspire Medical Systems, INC. | $30.77 | 2024 | Inspire |
| Vanda Pharmaceuticals INC. | $24.21 | 2025 | Fanapt |
| Corium, LLC | $22.81 | 2025 | Azstarys |
| Axsome Therapeutics, INC. | $21.67 | 2024 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.21 | 2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dafina Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.